---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-24-000241"
form_type: "8-K"
ticker: "CHE"
cik: "0000019584"
company_name: "CHEMED CORP"
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:25:38.866361+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Chemed Q3: rev $606M (+7.4%), adj EPS $5.64; FY2024 adj EPS guidance cut to $23.00-$23.15 on Roto-Rooter weakness

## Summary
- GAAP diluted EPS $5.00 (+1.4%); adjusted diluted EPS $5.64 (+6.0%).
- VITAS net patient revenue $391.4M (+17.3%), ADC 21,785 (+15.5%), adjusted EBITDA $73.1M (+33.1%).
- Roto-Rooter revenue $214.8M (-6.9%), adjusted EBITDA $56.4M (-15.8%), margin 26.3% (-275 bps).
- FY2024 adjusted EPS guidance revised to $23.00-$23.15 (targeting 13.3%-14.0% growth over 2023) due to softer Roto-Rooter results.
- Repurchased 100,000 shares for $57.8M at $578.21/share; cash $238.5M, no debt.

## SEC filing metadata
- accession: 0001562762-24-000241
- form_type: 8-K
- ticker: CHE
- cik: 0000019584
- company_name: CHEMED CORP
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/19584/000156276224000241/0001562762-24-000241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/19584/000156276224000241/che-20241029x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-24-000241
- JSON: https://secwatch.observer/filing/0001562762-24-000241.json
- Plain text: https://secwatch.observer/filing/0001562762-24-000241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.